Tscan Therapeutics Stock In The News

TCRX Stock  USD 4.64  0.13  2.73%   
Our overall analysis of Tscan Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Tscan Therapeutics. The specific impact of Tscan Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Tscan Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Tscan Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Tscan Therapeutics Backtesting and Tscan Therapeutics Hype Analysis.
For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide.

Tscan Therapeutics Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years
https://www.globenewswire.com/news-release/2023/11/30/2788469/0/en/TScan-Therapeutics-Named-Top-Place-to-Work-by-The-Boston-Globe-for-Two-Consecutive-Years.html
 Bullish
Macroaxis News: globenewswire.com
TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
https://www.globenewswire.com/news-release/2023/11/09/2777168/0/en/TScan-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html
 Bullish
Macroaxis News: globenewswire.com
TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting
https://www.globenewswire.com/news-release/2023/11/06/2773908/0/en/TScan-Therapeutics-Presents-Phase-1-Trial-Design-for-Solid-Tumor-Program-at-the-Society-for-Immunotherapy-of-Cancer-38th-Annual-Meeting.html
 Neutral
Macroaxis News: globenewswire.com
TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition
https://www.globenewswire.com/news-release/2023/11/02/2772436/0/en/TScan-Therapeutics-Announces-Upcoming-Presentation-at-the-65th-American-Society-of-Hematology-Annual-Meeting-and-Exposition.html
 Neutral
Macroaxis News: globenewswire.com
TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting
https://www.globenewswire.com/news-release/2023/09/27/2750474/0/en/TScan-Therapeutics-Announces-Upcoming-Presentations-at-the-38th-Society-for-Immunotherapy-of-Cancer-Annual-Meeting.html
 Neutral
Macroaxis News: globenewswire.com
Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors
https://www.globenewswire.com/news-release/2023/09/12/2741619/0/en/Sensorium-Therapeutics-Appoints-Veteran-Life-Sciences-Executive-Mr-David-Southwell-to-its-Board-of-Directors.html
 Bullish
Yahoo News
Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors
https://finance.yahoo.com/news/sensorium-therapeutics-appoints-veteran-life-120000047.html
 Bullish
Macroaxis News: globenewswire.com
TScan Therapeutics to Participate in Upcoming Investor Conferences
https://www.globenewswire.com/news-release/2023/09/05/2737155/0/en/TScan-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html
 Neutral
Macroaxis News: globenewswire.com
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME
https://www.globenewswire.com/news-release/2023/08/29/2733245/0/en/TScan-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-TSC-203-A0201-Targeting-PRAME.html
 Bullish
Macroaxis News: globenewswire.com
TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
https://www.globenewswire.com/news-release/2023/08/10/2722493/0/en/TScan-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html
 Bullish

Tscan Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Tscan and other traded companies coverage with news coverage. We help investors stay connected with Tscan headlines for the 28th of November to make an informed investment decision based on correlating the impacts of news items on Tscan Stock performance. Please note that trading solely based on the Tscan Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Tscan Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Tscan Therapeutics investors visualize upcoming and past events in order to time the market based on Tscan Therapeutics noise-free hype analysis.
Tscan Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Tscan earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Tscan Therapeutics that are available to investors today. That information is available publicly through Tscan media outlets and privately through word of mouth or via Tscan internal channels. However, regardless of the origin, that massive amount of Tscan data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Tscan Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Tscan Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Tscan Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Tscan Therapeutics alpha.

Tscan Largest EPS Surprises

Earnings surprises can significantly impact Tscan Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-11-12
2024-09-30-0.2918-0.250.041814 
2024-05-13
2024-03-31-0.26-0.32-0.0623 
2024-03-06
2023-12-31-0.29-0.210.0827 
2023-03-08
2022-12-31-0.7-0.78-0.0811 
2022-08-10
2022-06-30-0.75-0.630.1216 
2021-11-10
2021-09-30-0.64-0.8-0.1625 
View All Earnings Estimates

Tscan Therapeutics Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Tscan Therapeutics Stock. Current markets are slightly bullish. About 55% of major world exchanges and indexes are currently up. See today's market update for more information.
Investing News at Macroaxis
19th of November 2024
Tscan therapeutics sees 4,113 stock purchase by Lynx1 capital
at investing.com 
Investing News at Macroaxis
14th of November 2024
TScan Therapeutics SWOT analysis biotech stock poised for key catalysts
at investing.com 
Macroaxis News: globenewswire.com
12th of November 2024
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Upd...
at globenewswire.com 
Yahoo News
7th of November 2024
TScan Therapeutics Soars 7.6 percent Is Further Upside Left in the Stock
at finance.yahoo.com 
Yahoo News
5th of November 2024
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA Phase 1 He...
at finance.yahoo.com 
Yahoo News
4th of October 2024
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Ca...
at finance.yahoo.com 
Investing News at Macroaxis
24th of September 2024
TScan therapeutics director buys 26,450 in company stock
at investing.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Tscan Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Tscan Therapeutics' short interest history, or implied volatility extrapolated from Tscan Therapeutics options trading.

Additional Tools for Tscan Stock Analysis

When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.